These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 28638484)
41. Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. Pittella F; Cabral H; Maeda Y; Mi P; Watanabe S; Takemoto H; Kim HJ; Nishiyama N; Miyata K; Kataoka K J Control Release; 2014 Mar; 178():18-24. PubMed ID: 24440662 [TBL] [Abstract][Full Text] [Related]
42. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529 [TBL] [Abstract][Full Text] [Related]
43. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615 [TBL] [Abstract][Full Text] [Related]
44. PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability. Godinho BM; Ogier JR; Quinlan A; Darcy R; Griffin BT; Cryan JF; O'Driscoll CM Int J Pharm; 2014 Oct; 473(1-2):105-12. PubMed ID: 24992319 [TBL] [Abstract][Full Text] [Related]
45. Acute in vivo toxicity mitigation of PEI-coated maghemite nanoparticles using controlled oxidation and surface modifications toward siRNA delivery. Israel LL; Lellouche E; Ostrovsky S; Yarmiayev V; Bechor M; Michaeli S; Lellouche JP ACS Appl Mater Interfaces; 2015 Jul; 7(28):15240-55. PubMed ID: 26120905 [TBL] [Abstract][Full Text] [Related]
46. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487 [TBL] [Abstract][Full Text] [Related]
47. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Li TS; Yawata T; Honke K Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005 [TBL] [Abstract][Full Text] [Related]
48. Structural contributions of blocked or grafted poly(2-dimethylaminoethyl methacrylate) on PEGylated polycaprolactone nanoparticles in siRNA delivery. Lin D; Huang Y; Jiang Q; Zhang W; Yue X; Guo S; Xiao P; Du Q; Xing J; Deng L; Liang Z; Dong A Biomaterials; 2011 Nov; 32(33):8730-42. PubMed ID: 21885115 [TBL] [Abstract][Full Text] [Related]
49. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. Li J; Chen YC; Tseng YC; Mozumdar S; Huang L J Control Release; 2010 Mar; 142(3):416-21. PubMed ID: 19919845 [TBL] [Abstract][Full Text] [Related]
50. Doping hydroxylated cationic lipid into PEGylated cerasome boosts in vivo siRNA transfection efficacy. Li Y; Zheng S; Liang X; Jin Y; Wu Y; Bai H; Liu R; Dai Z; Liang Z; Shi T Bioconjug Chem; 2014 Nov; 25(11):2055-66. PubMed ID: 25260060 [TBL] [Abstract][Full Text] [Related]
51. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158 [TBL] [Abstract][Full Text] [Related]
52. RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications. Andersen MØ; Howard KA; Kjems J Methods Mol Biol; 2009; 555():77-86. PubMed ID: 19495689 [TBL] [Abstract][Full Text] [Related]
53. Synthesis of PLGA-Lipid Hybrid Nanoparticles for siRNA Delivery Using the Emulsion Method PLGA-PEG-Lipid Nanoparticles for siRNA Delivery. Wang L; Griffel B; Xu X Methods Mol Biol; 2017; 1632():231-240. PubMed ID: 28730443 [TBL] [Abstract][Full Text] [Related]
54. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Iversen F; Yang C; Dagnæs-Hansen F; Schaffert DH; Kjems J; Gao S Theranostics; 2013; 3(3):201-9. PubMed ID: 23471415 [TBL] [Abstract][Full Text] [Related]
55. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Li SD; Huang L Biochim Biophys Acta; 2009 Oct; 1788(10):2259-66. PubMed ID: 19595666 [TBL] [Abstract][Full Text] [Related]
56. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802 [TBL] [Abstract][Full Text] [Related]
57. Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide-siRNA Nanocomplexes. Lo JH; Kwon EJ; Zhang AQ; Singhal P; Bhatia SN Bioconjug Chem; 2016 Oct; 27(10):2323-2331. PubMed ID: 27583545 [TBL] [Abstract][Full Text] [Related]